Repurposing Statins for Renal Protection: Is It a Class Effect?

McWilliam, Stephen; Antoine, Daniel J.; Pirmohamed, Munir

doi:10.1111/cts.12521

Cited by 9 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The collinearity of hypertension and hyperlipidemia may explain this phenomenon. In addition, the use of lipidlowering drugs may have renal protective effects that alleviate the renal toxicity associated with sleeping pill use (McWilliam et al, 2018). Individuals with low insurance premiums are often equal to the group with a low socioeconomic status in Taiwan who were at risk of CKD events in our study.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Taking Sleeping Pills and the Risk of Chronic Kidney Disease: A Nationwide Population-Based Retrospective Cohort Study

Liao

Chung

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Sleeping disorder has been associated with chronic kidney disease (CKD); however, the correlation between sleeping pills use and CKD has not been investigated in-depth yet. This study elucidated the potential association of sleeping pill use with the risk of CKD and CKD progression to end-stage renal disease (ESRD) requiring dialysis.Methods: This study was based on a population-based cohort that included 209,755 sleeping pill users among 989,753 individuals. After applying the exclusion criteria, 186,654 sleeping pill users and 373,308 nonusers were enrolled to monitor the occurrence of CKD. Using a cumulative daily dose, we analyzed the types of sleeping pills related to the risk of CKD and ESRD. Propensity score matching and analysis using Cox proportional hazards regression were performed with adjustments for sex, age, and comorbidities.Results: Sleeping pill use was related to increased CKD risk after adjusting for underlying comorbidities (adjusted hazard ratio [aHR] = 1.806, 95% confidence interval [CI]: 1.617–2.105, p < 0.001). With the exception of hyperlipidemia, most comorbidities correlated with an increased risk of CKD. Persistent use of sleeping pills after CKD diagnosis increased the risk of concurrent ESRD (aHR = 7.542; 95% CI: 4.267–10.156; p < 0.001). After the subgroup analysis for sleeping pill use, brotizolam (p = 0.046), chlordiazepoxide (p < 0.001), clonazepam (p < 0.001), diazepam (p < 0.001), dormicum (p < 0.001), estazolam (p < 0.001), fludiazepam (p < 0.001), flunitrazepam (p < 0.001), nitrazepam (p < 0.001), trazodone (p < 0.001), zolpidem (p < 0.001), and zopiclone (p < 0.001) were found to have significant correlation with increased CKD risk.Conclusion: Sleeping pill use was related to an increased risk of CKD and ESRD. Further studies are necessary to corroborate these findings.

show abstract

Section: Discussionmentioning

confidence: 87%

“…The collinearity of hypertension and hyperlipidemia may explain this phenomenon. In addition, the use of lipid-lowering drugs may have renal protective effects that alleviate the renal toxicity associated with sleeping pill use ( McWilliam et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Taking Sleeping Pills and the Risk of Chronic Kidney Disease: A Nationwide Population-Based Retrospective Cohort Study

Liao

Chung

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Investigation of this unexpected effect is a frequent driver for working backwards to reevaluate an old drug. Though it is more ideal to stay within the T1-T3 phases during reevaluation, many of these clinically relevant questions require investigations at the basic science level (Becker and Funk, 2018;McWilliam et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing

Boyd

Teng

Frei

2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Drug repurposing, or identifying new uses for existing drugs, has emerged as an alternative to traditional drug discovery processes involving de novo synthesis. Drugs that are currently approved or under development for non-antibiotic indications may possess antibiotic properties, and therefore may have repurposing potential, either alone or in combination with an antibiotic. They might also serve as “antibiotic adjuvants” to enhance the activity of certain antibiotics.

show abstract

“…Известно, что высокодозовый прием высокоэффективных статинов предотвращает развитие контраст-индуцированной нефропатии [110]. Активно обсуждается как профилактическое [111], так и негативное [112] влияние статинов на развитие ОПП после проведения кардиохирургии и других операций [113]. Имеются мета-анализы и систе-матические обзоры, не подтвердившие роль статинов в снижении риска почечной недостаточности [98,114,115].…”

Section: обзоры §unclassified

The problem of safety of lipid-lowering therapy

Зыков

2019

Kardiologiia

View full text Add to dashboard Cite

This study focused on analysis of current publications evaluating safety of lipid-lowering therapy. Search for literature was performed on websites of cardiological societies and online databases, including PubMed, EMBASE, and eLibrary by the following key words: statins, statin intolerance, lipid-lowering therapy, statin safety, and statin аdverse effects. The focus is on statins, in view of the fact that they are the most commonly prescribed, highly effective and safe drugs for primary and secondary cardiovascular prophylaxis. This review consistently summarized information about myopathies, hepatic and renal dysfunction, potentiation of DM, and other possible adverse effects of lipid-lowering therapy. The author concluded that despite the high safety of statins acknowledged by all international cardiological societies, practicing doctors still continue unreasonably cancel statins, exposing the patient under even greater danger. Information about the corresponding author:

show abstract

Repurposing Statins for Renal Protection: Is It a Class Effect?

Cited by 9 publications

References 10 publications

Taking Sleeping Pills and the Risk of Chronic Kidney Disease: A Nationwide Population-Based Retrospective Cohort Study

Taking Sleeping Pills and the Risk of Chronic Kidney Disease: A Nationwide Population-Based Retrospective Cohort Study

Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing

The problem of safety of lipid-lowering therapy

Contact Info

Product

Resources

About